Home > List All Publishers > VacZine Analytics

VacZine Analytics

VacZine Analytics is an established strategic research consultancy based in the United Kingdom. Its specific aim is to provide high-quality disease and commercial analysis to those working within or in collaboration with the growing vaccine/biologics industry. Through our “custom” and “off the shelf” syndicated product lines the key focus of the company is to help clients build the case for developing new vaccines.

List of reports from VacZine Analytics

Disease INFOPACK: Acinetobacter baumannii 10/1/2007 \| published by: VacZine Analytics ... range between 30-75%. Of greatest concern is the high intrinsic drug resistance of the most common type Acinetobacter baumannii which forces physicians to use older drugs such as polymixins and colistin with low tolerability profiles. ... \| more... Search inside this report	$4,595.00
Disease INFOPACK: Foot-and-mouth disease 10/1/2007 \| published by: VacZine Analytics ... infected animals and spread very rapidly. The most significant feature of foot-and-mouth disease is its devastating economic impact with the cost of the 2001 UK epidemic estimated between $12-13 billion. This DiseaseINFOPACK report is an ... \| more... Search inside this report	$4,595.00
Disease INFOPACK: ESBL-producing E.coli 10/1/2007 \| published by: VacZine Analytics ... hospital settings. In rare cases ExPEC can also cause bloodstream infections which lead to sepsis and even death. Since the 1980s, hospital E.coli has become multidrug resistant through the production of extended-spectrum beta-lactamase enzymes (ESBLs). ... \| more... Search inside this report	$4,595.00
Vaccine Intellectual Property Review 4/1/2008 \| published by: VacZine Analytics ... Analytics has created a unique database (~300 patents) mapping the current vaccine intellectual property landscape pertaining to potential vaccine antigens and their commercial use in vaccines. Summary analyses of the database reveal striking differences between ... \| more...	$10,995.00
Disease INFOPACK: Chlamydia trachomatis 5/1/2008 \| published by: VacZine Analytics ... pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are “silent” and unrecognized. This is of concern due to continued transmission especially ... \| more... Search inside this report	$4,595.00
Disease INFOPACK: Community-acquired MRSA 5/1/2008 \| published by: VacZine Analytics ... severe disease in previously healthy persons with no history of contact with the hospital setting. CA-MRSA is transmitted from person-to-person with disease outbreaks being reported in competitive sportsmen, inmates and day-care attendees. This DiseaseINFOPACK report ... \| more... Search inside this report	$4,595.00
Disease INFOPACK: Respiratory Syncytial Virus (elderly) 6/1/2008 \| published by: VacZine Analytics ... RSV is a common pathogen in infants it also causes significant disease burden in adults with a compromised immune or respiratory system such as the elderly or those with chronic obstructive pulmonary disease (COPD). This ... \| more... Search inside this report	$4,595.00
Disease INFOPACK: Group A Strep (invasive) 7/1/2008 \| published by: VacZine Analytics ... infections range from mild superficial infections such as pharyngitis “strep throat” to severe invasive life-threatening diseases such as necrotizing fasciitis (NF) or “flesh eating disease”. GAS is also responsible for rheumatic heart disease which is ... \| more... Search inside this report	$4,595.00
MarketVIEW: Clostridium difficile Vaccines 8/1/2008 \| published by: VacZine Analytics ... forecasting the potential commercial value of a prophylactic C.diff vaccine across the seven major markets. The model contains value ($ m) and volume (mio doses) estimates in both community and hospitalized populations along with predictions ... \| more...	$8,995.00
OpportunitySCAN: Clostridium difficile vaccines 8/1/2008 \| published by: VacZine Analytics ... regarding current disease dynamics and the scientific viability of immunologic based strategies. Within the document, the reader can access target product profiles (TPPs) for the vaccine in the pre-exposure and therapeutic settings, along definition of ... \| more...	$8,995.00
Disease INFOPACK: Norovirus 9/1/2008 \| published by: VacZine Analytics ... the elderly in long-term care facilities and hospitals. Although Noroviruses cause a mild illness of short duration, severe dehydration or electrolyte imbalance can be a contributing cause to death in vulnerable populations. Significantly, current evidence ... \| more...	$4,595.00
OpportunitySCAN: Staphylococcus aureus vaccines 9/1/2008 \| published by: VacZine Analytics ... and EU regarding current disease dynamics and the scientific viability of immunologic based strategies. Within the document, the reader can access target product profiles (TPPs) for the vaccine, along with definition of target populations and ... \| more...	$8,995.00
Vaccine Pipeline Review - Oct 2008 10/1/2008 \| published by: VacZine Analytics ... companies. It can be used for competitive intelligence, business development and strategic planning activities. In the database, each program comes with predicted BLA and MAA filing dates along with key details such as clinical trial ... \| more...	$8,995.00
MarketVIEW: pre-pandemic vaccines 3/1/2009 \| published by: VacZine Analytics ... has caused high mortality in poultry and occasionally infects humans in close contact with around 60% of cases (408) so far being fatal. As of February 27th 2009 confirmed H5N1 Avian influenza deaths in humans ... \| more... Search inside this report	$8,995.00
Diseaseinfopack: Pre-pandemic Vaccines 3/1/2009 \| published by: VacZine Analytics ... H5N1 Avian influenza deaths in humans have reached 256, a significant increase upon 2004 when measurements began. This expert report provides a comprehensive up-to-date critical review of current global pandemic preparedness and planning with regard ... \| more... Search inside this report	$6,995.00
DiseaseINFOPACK: Non-typeable Haemophilus influenzae 3/1/2009 \| published by: VacZine Analytics ... and adults. In the US, the Centers For Disease Control (CDC) and Prevention estimates that H.influenzae caused greater than 4,500 cases of invasive disease resulting in 405 deaths in 2007 of which around 60% of ... \| more... Search inside this report	$4,895.00
DiseaseINFOPACK: Chikungunya virus 5/1/2009 \| published by: VacZine Analytics ... disease (encephalopathy). Although CHIK is endemic in Africa/Southeast Asia, recent outbreaks during 2004-2007 have reached new geographical areas where cases are now reported in Europe, Hong-Kong, Canada, Taiwan and the USA. In some cases, these ... \| more...	$4,895.00
MarketVIEW: H1N1 vaccine (US demand model) 5/1/2009 \| published by: VacZine Analytics ... infection with over half of the cases being identified in the continental United States. Using currently available information regarding the expected profile, possible allocation of H1N1 specific vaccine and predictions of pandemic severity, VacZine Analytics ... \| more...	$1,995.00
MarketVIEW: Chikungunya virus 6/1/2009 \| published by: VacZine Analytics ... many organizations, including biotechs and the US/French military have considered the prospect for a prophylatic vaccine which could be used in stationed troops, travellers and vulnerable residents of endemic areas. This expert report comprises of ... \| more...	$7,995.00
DiseaseINFOPACK: Enterovirus-71 8/1/2009 \| published by: VacZine Analytics ... significance, EV-71 appears an attractive target for a vaccine-based preventative approach. This expert DiseaseINFOPACK report gives a comprehensive situation overview of current EV-71 disease dynamics and regional epidemiology. EV-71 is under consideration by a number ... \| more... Search inside this report	$4,895.00
DiseaseINFOPACK: Streptococcus dysgalactiae 9/1/2009 \| published by: VacZine Analytics ... Streptococcus (GAS) (1). These diseases include superficial skin infections, pharyngitis and life threatening conditions such as Streptococcal toxic shock syndrome (STSS). SDSE may express group A, group C or group G Lancefield antigens, but generally ... \| more... Search inside this report	$4,895.00
MarketVIEW: H1N1 vaccine (Global demand model) 9/1/2009 \| published by: VacZine Analytics ... confirmed cases and 4500 reported deaths globally due to the virus. Vaccine manufacturers are now actively producing H1N1 pandemic specific vaccines which are now reaching regulatory approval in the US and EU. The US ACIP ... \| more...	$5,995.00
MarketVIEW: Group B Streptococcus vaccines 9/1/2009 \| published by: VacZine Analytics ... threatening sepsis and meningitis (early and late onset disease) due to ascending spread of GBS from the birth canal of colonized females (~30% of total) who are typically asymptomatic. In the 1970s GBS was the ... \| more...	$6,995.00
DiseaseINFOPACK: Clostridium difficile in China 11/1/2009 \| published by: VacZine Analytics ... C.diff epidemiology is accumulating in Western markets, a lot less is known in large emerging nations such as China. Information is required to understand whether the extent of disease epidemiology and associated dynamics is similar ... \| more... Search inside this report	$4,895.00
MarketVIEW: Meningitis ACWY vaccines 3/1/2010 \| published by: VacZine Analytics ... where 5 main serogroups ACWY and B are responsible for the majority of disease. Conjugated vaccines to prevent meningococcal disease have had successful impact especially in the United Kingdom (serogroup C, implemented 1999). In 2005, ... \| more...	$7,995.00

< prev 1 2 next >